-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Dengue -X- _ B-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
DENV -X- _ I-Patient
) -X- _ I-Patient
still -X- _ O
poses -X- _ O
a -X- _ O
global -X- _ O
public -X- _ O
health -X- _ O
threat -X- _ O
, -X- _ O
and -X- _ O
no -X- _ O
vaccine -X- _ O
or -X- _ O
antiviral -X- _ O
therapy -X- _ O
is -X- _ O
currently -X- _ O
available. -X- _ O
Antibody -X- _ O
plays -X- _ O
distinct -X- _ O
roles -X- _ O
in -X- _ O
controlling -X- _ O
DENV -X- _ B-Patient
infections. -X- _ I-Patient
Neutralizing -X- _ O
antibody -X- _ O
is -X- _ O
protective -X- _ O
against -X- _ O
DENV -X- _ B-Patient
infection -X- _ I-Patient
, -X- _ O
whereas -X- _ O
sub-neutralizing -X- _ O
concentration -X- _ O
of -X- _ O
antibody -X- _ O
can -X- _ O
increase -X- _ O
DENV -X- _ O
infection -X- _ O
, -X- _ O
termed -X- _ O
antibody-dependent -X- _ O
enhancement -X- _ O
( -X- _ O
ADE -X- _ O
) -X- _ O
. -X- _ O
Plaque-based -X- _ O
assay -X- _ O
represents -X- _ O
the -X- _ O
most -X- _ O
widely -X- _ O
accepted -X- _ O
method -X- _ O
measuring -X- _ O
neutralizing -X- _ O
or -X- _ O
enhancing -X- _ O
antibodies. -X- _ O
RESULTS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
a -X- _ B-Outcome
novel -X- _ I-Outcome
reporter -X- _ I-Outcome
virus- -X- _ I-Outcome
based -X- _ I-Outcome
system -X- _ I-Outcome
was -X- _ I-Outcome
developed -X- _ I-Outcome
for -X- _ I-Outcome
measuring -X- _ I-Outcome
neutralization -X- _ I-Outcome
and -X- _ I-Outcome
ADE -X- _ I-Outcome
activity. -X- _ I-Outcome
A -X- _ I-Outcome
stable -X- _ I-Outcome
Renilla -X- _ I-Outcome
luciferase -X- _ I-Outcome
reporter -X- _ I-Outcome
DENV -X- _ I-Outcome
( -X- _ I-Outcome
Luc-DENV -X- _ I-Outcome
) -X- _ I-Outcome
that -X- _ I-Outcome
can -X- _ I-Outcome
produce -X- _ I-Outcome
robust -X- _ I-Outcome
luciferase -X- _ I-Outcome
signals -X- _ I-Outcome
in -X- _ I-Outcome
BHK-21 -X- _ I-Outcome
and -X- _ I-Outcome
K562 -X- _ I-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
used -X- _ I-Outcome
to -X- _ I-Outcome
establish -X- _ I-Outcome
the -X- _ I-Outcome
assay -X- _ I-Outcome
and -X- _ I-Outcome
validated -X- _ I-Outcome
against -X- _ I-Outcome
traditional -X- _ I-Outcome
plaque-based -X- _ I-Outcome
assay. -X- _ I-Outcome
Luciferase -X- _ I-Outcome
value -X- _ I-Outcome
analysis -X- _ I-Outcome
using -X- _ I-Outcome
various -X- _ I-Outcome
known -X- _ I-Outcome
DENV-specific -X- _ I-Outcome
monoclonal -X- _ I-Outcome
antibodies -X- _ I-Outcome
showed -X- _ I-Outcome
good -X- _ I-Outcome
repeatability -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
well -X- _ I-Outcome
linear -X- _ I-Outcome
correlation -X- _ I-Outcome
with -X- _ I-Outcome
conventional -X- _ I-Outcome
plaque-based -X- _ I-Outcome
assays. -X- _ I-Outcome
The -X- _ I-Outcome
newly -X- _ I-Outcome
developed -X- _ I-Outcome
assay -X- _ I-Outcome
was -X- _ I-Outcome
finally -X- _ I-Outcome
validated -X- _ I-Outcome
with -X- _ I-Outcome
clinical -X- _ I-Outcome
samples -X- _ I-Outcome
from -X- _ I-Outcome
infected -X- _ I-Outcome
animals -X- _ I-Outcome
and -X- _ I-Outcome
individuals. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
This -X- _ O
reporter -X- _ O
virus-based -X- _ O
assay -X- _ O
for -X- _ O
neutralizing -X- _ O
and -X- _ O
enhancing -X- _ O
antibody -X- _ O
evaluation -X- _ O
is -X- _ O
rapid -X- _ O
, -X- _ O
lower -X- _ O
cost -X- _ O
, -X- _ O
and -X- _ O
high -X- _ O
throughput -X- _ O
, -X- _ O
and -X- _ O
will -X- _ O
be -X- _ O
helpful -X- _ O
for -X- _ O
laboratory -X- _ O
detection -X- _ O
and -X- _ O
epidemiological -X- _ O
investigation -X- _ O
for -X- _ O
DENV -X- _ O
antibodies -X- _ O
. -X- _ O

